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Cutting Edge: IL-6–Driven Immune Dysregulation Is
Strictly Dependent on IL-6R a-Chain Expression
Ilgiz A. Mufazalov,*,† David Andruszewski,* Carsten Schelmbauer,* Sylvia Heink,‡
Michaela Blanfeld,* Joumana Masri,* Yilang Tang,* Rebecca Schu¨ler,*,x,{
Christina Eich,* F. Thomas Wunderlich,‖,# Susanne H. Karbach,*,x,{ Jeffrey A. Bluestone,†
Thomas Korn,‡,**,1 and Ari Waisman*,1
IL-6 binds to the IL-6R a-chain (IL-6Ra) and signals via
the signal transducer gp130. Recently, IL-6 was found
to also bind to the cell surface glycoprotein CD5, which
would then engage gp130 in the absence of IL-6Ra.
However, the biological relevance of this alternative
pathway is under debate. In this study, we developed a
mouse model, in which murine IL-6 is overexpressed in
a CD11c-Cre–dependent manner. Transgenic mice de-
veloped a lethal immune dysregulation syndrome with
increased numbers of Ly-6G+ neutrophils and Ly-6Chi
monocytes/macrophages. IL-6 overexpression promoted
activation of CD4+ T cells while suppressing CD5+ B-1a
cell development. However, additional ablation of
IL-6Ra protected IL-6–overexpressing mice from
IL-6–triggered inflammation and fully phenocopied
IL-6Ra–deficient mice without IL-6 overexpression.
Mechanistically, IL-6Ra deficiency completely prevented
downstream activation of STAT3 in response to IL-6.
Altogether, our data clarify that IL-6Ra is the only bi-
ologically relevant receptor for IL-6 in mice. The
Journal of Immunology, 2020, 204: 747–751.
E
levated levels of IL-6 have been observed in numerous
pathological conditions, and several drugs are suc-
cessfully used in a series of human diseases, including
rheumatoid arthritis, Castleman disease, and giant cell arteritis
to target IL-6 and its receptor, IL-6R a-chain (IL-6Ra) (1). For
other diseases like multiple myeloma and neuromyelitis optica,
the clinical program for the development of IL-6–neutralizing
agents is very advanced, and drugs targeting IL-6 or IL-6Ra
might be licensed for these diseases in the near future (2).
IL-6, together with IL-11, IL-27, CNTF, LIF, OSM, CT-1,
and CLC, belongs to the group of cytokines that use gp130 for
signal transduction (3). Since its discovery in 1990, it was
believed that the IL-6–signaling complex consists of a unique
IL-6–binding receptor IL-6Ra (also known as CD126) and
the signal transducer gp130 (4). The assembly of IL-6,
IL-6Ra, and gp130 leads to activation of STAT3-mediated
intracellular signaling pathways, which control cell survival,
activation, and proliferation (2). IL-6Ra also exists in a sol-
uble form, which is generated via secretion or shedding of
membrane-bound IL-6Ra. The complex of IL-6 and soluble
IL-6Ra is able to bind to gp130 and then induce STAT3
phosphorylation in cells that do not express IL-6Ra them-
selves. This signaling modality of IL-6 was termed IL-6 trans-
signaling (5). A third modality of IL-6 signaling, called IL-6
cluster signaling, is mediated by cell-bound presentation of
the IL-6/IL-6Ra complex in trans by a donor cell to a receiving
cell that expresses gp130 (2, 6). In both IL-6 trans-signaling
and IL-6 cluster signaling, cells that express gp130, but lack
IL-6Ra, still respond to IL-6.
In 2016, an alternative pathway of IL-6 signal transduction
was proposed in which IL-6 binds to the membrane-anchored
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glycoprotein CD5 instead of IL-6Ra and, via gp130, initiates
STAT3 phosphorylation in B cells (7). This study suggested
the CD5-dependent pathway of IL-6 signaling was critical in
the promotion of cancer progression (7). However, the mecha-
nism for this novel IL-6 binding was not elucidated. In fact,
soluble CD5, despite binding to IL-6, is unable to induce IL-6
trans-signaling (8). Massive overproduction of IL-6 is observed
in sepsis (9) and has been reported during the cytokine release
syndrome in response to CAR–T cell immune therapies (10). To
keep exaggerated IL-6 responses in check, any design of ther-
apeutic intervention needs to consider potential alternative
signaling pathways of IL-6. In particular, the idea of CD5 as a
molecule to substitute for IL-6Ra in forming the IL-6 signal
transduction complex might be relevant in this context.
To test whether IL-6Ra can be functionally replaced in any
IL-6–signaling modality, we used a set of genetically modified
mice with IL-6 overexpression. High levels of IL-6 led to sys-
temic inflammation, which subsequently resulted in a lethal
outcome. In contrast, mice that overexpressed IL-6, but lacked
IL-6Ra, did not show STAT3 phosphorylation and were
completely protected from IL-6–mediated pathology, sug-
gesting that IL-6Ra is indispensable for IL-6 signaling.
Materials and Methods
Mice
Mice with conditional Il6ra allele (Il6ra flox) (11) and CD11c-Cre mice (12)
have been previously described. IL-6Ra full-knockout (Il6ra2/2) mice were
selected from the breeding between Il6ra flox mice and CD11c-Cre mice,
which displayed occasional spontaneous germline Cre activity. Principles used
to generate mice with the knock-in of a transgene into Rosa26 locus have been
previously described (13). Details of the generation of mice carrying murine
cDNA in the CAG–(loxP)STOP(loxP)–IL-6–IRES–eGFP transgene inserted
in the Rosa26 locus will be reported elsewhere. For breeding strategies involving
IL-6 overexpression and mouse group abbreviations, refer to Supplemental
Fig. 1A. All mice were on C57BL/6 background and were bred in-house
under specific pathogen-free conditions. For experiments, 5–9-wk-old, gender-
matched mice were used in accordance with the guidelines of the central animal
facility institution (Translational Animal Research Center, University of Mainz).
Mouse sample collection
Single-cell suspensions from spleen and lymph nodes were prepared by me-
chanical dissociation in PBS supplemented with 2% FCS. Peritoneal lavage was
performed on lethally anesthetized mice with 5 ml of PBS supplemented with
3% FCS. Peripheral blood was collected from the tail vein. RBCs were removed
using ACK lysis buffer.
IL-6 ELISA
A murine IL-6 ELISA Kit (BD Biosciences) was used to analyze IL-6 levels
in the blood serum. Plates were measured with the Infinite M200 PRO
NanoQuant reader (Tecan).
Flow cytometry
Single-cell suspensions were stained with Abs together with viability dyes
(Supplemental Table I). Stained cells were acquired on FACSCanto II (BD
Biosciences), and data were analyzed with FlowJo software. Gating strategy
always considered cell size, excluded duplets, and defined living cells as via-
bility dye–negative (VD2) population.
p-STAT3 detection by flow cytometry
Peritoneal lavage preparations pooled from four to five mice per genotype
were FACS sorted for CD42F4/802CD19+CD52 cells and for CD42F4/
802CD19+CD5+ cells, using FACSAria III (BD Biosciences). Splenocytes
pooled from four to five mice per genotype were FACS sorted for
CD192CD4+CD5+ cells. Sorted cells from Il6ra2/2 mice (CD45.2) were
mixed at 1:1 ratio with wild-type Il6ra+/+ cells (CD45.1) in U-button,
96-well plates (total amount of 1.0 3 106 cells), rested for 1 h in 200 ml
of complete DMEM medium at 37˚C, and stimulated with 50 ng/ml
human IL-6 (Miltenyi Biotec) or 125 ng/ml of human IL-6/IL-6Ra
complex (hyper–IL-6, kindly provided by the group of Dr. Rose-John,
Kiel, Germany), which represents an equimolar amount as compared with
the condition with soluble IL-6 only. Samples were fixed (Phosflow Lyse/
Fix Buffer 53; BD Biosciences) and permeabilized (Phosflow Perm Buffer
III; BD Biosciences) according to the manufacturer’s recommendations.
Afterwards, cells were stained with CD45.2-BV650, CD45.1-FITC, and
p-STAT3(Y705)-PE FACS Abs in PBS supplemented with 2% FCS. Stained
cells were acquired on a CytoFLEX flow cytometer (Beckman Coulter) and
analyzed with FlowJo software.
Immunoblotting
CD19+ B cells and CD4+ T cells were isolated using MACS technology
(Miltenyi Biotec) from pooled spleen and lymph node preparations. For
stimulation, (0.4–8.0) 3 106 cells pooled from individual mice (three to four
per genotype) were incubated in 100 ml of complete RPMI medium at 37˚C
in the presence of recombinant murine IL-6 (PromoKine) and, afterward,
were lysed in radioimmunoprecipitation assay buffer. Lysates were sepa-
rated by SDS-PAGE (NuPAGE; Invitrogen) and transferred to polyvi-
nylidene difluoride membranes (MilliporeSigma). Protein blots were probed
with anti-phosphotyrosine 705 STAT3, anti-total STAT3 (Cell Signaling),
and anti–b-actin (Sigma-Aldrich). For detection, goat anti-rabbit (Santa Cruz
Biotechnology) IgG-HRP–linked secondary Abs were used.
Statistical analysis
Statistical analysis and graphical representation were performed with Prism 5
software (GraphPad). Statistical significance was calculated using the unpaired
two-tailed t test and Gehan–Breslow–Wilcoxon test for Kaplan–Meier sur-
vival curves. The p values, 0.05,, 0.01, and, 0.001 were marked as *, **,
and ***, respectively.
Results and Discussion
The cytokine IL-6 uses various signaling modalities (i.e., classic
signaling, trans-signaling, and cluster signaling [also called trans-
presentation]) (2) and might even signal through an alternative
receptor complex composed of CD5 and gp130 (7). To assess
the signaling modality of IL-6 under conditions of exagger-
ated IL-6 production, we created a murine system of sterile
IL-6 overexpression in vivo. To this end, we generated mice
carrying a CAG–(loxP)STOP(loxP)–IL-6–IRES–eGFP
construct in the Rosa26 locus. Next, we used dendritic cell
(DC)–directed CD11c-Cre transgenic mice (12) to activate
IL-6 overexpression (OE) from a single copy of our Il6 trans-
gene in mice on an IL-6Ra–sufficient background (IL-6DC-OE
Il6ra+/+ and IL-6DC-OE Il6ra+/2 [i.e., IL-6DC-OE]) and on
an IL-6Ra–deficient background (IL-6DC-OE Il6ra2/2). As
further controls, we used IL-6Ra–sufficient (control) and
IL-6Ra–deficient (Il6ra2/2) mice without IL-6 overexpression
(Supplemental Fig. 1A).
To directly assess IL-6 overexpression, we measured IL-6
levels in the serum of 5–6-wk-old mutant mice. As expected,
both groups of mice with IL-6 overexpression showed elevated
levels of IL-6 in comparison with wild-type controls and
Il6ra2/2 mice (Fig. 1A). IL-6 levels were significantly higher
in IL-6DC-OE mice than in IL-6DC-OE Il6ra2/2 mice, suggest-
ing a positive feed-forward loop for IL-6 expression in mice
sufficient for IL-6Ra. Mechanistically, transgenic IL-6 can
promote IL-6 expression in IL-6DC-OE mice, from the en-
dogenous Il6 locus, which remained responsive to its natural
regulation. In addition, IL-6 forms a complex with the sol-
uble IL-6Ra and gp130 in the blood, which can prolong
its half-life only in IL-6Ra–sufficient, but not in IL-6Ra–
deficient, mice (14, 15).
To analyze cellular sources of transgenic IL-6, we assessed
eGFP reporter expression driven by the CAG promoter after
CD11c-Cre mediated excision of the loxP flanked STOP
cassette. As expected, we found eGFP expression in DCs in
IL-6DC-OE and IL-6DC-OE Il6ra2/2mice (Fig. 1B, Supplemental
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Fig. 1C). Because of leakiness of the CD11c-Cre recombinase
expression (16), we also noted limited reporter expression
in other myeloid cells and in T and B cells of these mice
(Supplemental Fig. 1C).
High systemic levels of IL-6 ultimately led to the death of
IL-6DC-OE mice in an IL-6Ra–dependent manner (Fig. 1C).
IL-6–overexpressing mice carrying both copies of Il6ra died
within 6 wk of age, whereas deletion of one Il6ra allele (with
one Il6ra allele intact in heterozygous Il6ra+/2 mice) extended
the survival of IL-6DC-OE mice until 11 wk of age. Strikingly,
null deficiency in Il6ra restored the survival of IL-6DC-OE
Il6ra2/2mice with IL-6 overexpression and, thus, fully res-
cued the phenotype of IL-6DC-OE mice. Of note, 3 out of 41
Il6ra2/2 mice died during the observation period presum-
ably because of their immunodeficiency (17), irrespective of
IL-6 overexpression.
To study the impact of IL-6Ra expression on IL-6 signaling,
we isolated splenocytes from wild-type (Il6ra+/+), Il6ra+/2, and
Il6ra2/2 mice. We observed a robust IL-6Ra expression on
CD4+ T cells and, to a lesser extent, on CD11b+ myeloid cells,
but very limited expression on CD19+ B cells in wild-type mice
(Fig. 1D). Deletion of a single Il6ra allele led to reduction in
IL-6Ra expression, suggesting a haploinsufficient gene dose
effect (Fig. 1D), which, together with reduced frequencies of
IL-6Ra–positive cells in Il6ra+/2 mice (Supplemental Fig.
2A), may contribute to the reduced mortality of IL-6DC-OE
Il6ra+/2 mice in comparison with IL-6DC-OE Il6ra+/+ mice
(Fig. 1C). To determine the consequence of the lack of
IL-6Ra in downstream signaling events, we stimulated total
splenocytes isolated from Il6ra+/+, Il6ra+/2, and Il6ra2/2 mice
with IL-6 and assessed their STAT3 phosphorylation. We
observed STAT3 phosphorylation only in wild-type and Il6ra
heterozygous cells, whereas Il6ra2/2 splenocytes were irrespon-
sive to stimulation with soluble IL-6 (Fig. 1E, Supplemental
Fig. 2B). FACS-sorted CD52 and CD5+ B cells, as well as
CD5+ T cells, isolated from Il6ra2/2 mice did not respond to
soluble IL-6 either, whereas their wild-type counterparts
showed a clear STAT3 activation in response to soluble IL-6
(Supplemental Fig. 2C). In contrast, IL-6Ra–deficient B cells
(regardless of CD5 expression), and IL-6Ra–deficient T cells
responded to IL-6 in the presence of exogenous IL-6Ra in the
form of hyper–IL-6, which represents IL-6/IL-6Ra fusion
protein (Supplemental Fig. 2C). These data indicate that
Il6ra2/2 cells retain the ability to respond to IL-6 trans-
signaling, whereas IL-6Ra expression on the cell surface is
nonredundant for classic IL-6 signaling. Together, this refutes
the concept that alternative receptor molecules can compensate
for the lack of IL-6Ra expression.
As a consequence of IL-6 overexpression, CD11b+ myeloid
cells massively infiltrated secondary lymphoid organs, result-
ing in splenomegaly of IL-6Ra–sufficient IL-6DC-OE mice
(Supplemental Fig. 3). The most dramatic increase in re-
sponse to transgenic IL-6 was observed in Ly-6G+ neutrophils
and Ly-6Chi monocytes/macrophages (Fig. 2A). Notably, the
systemic increase in these myeloid cell subsets was completely
abrogated in IL-6DC-OE Il6ra2/2 mice lacking IL-6Ra. It is
likely that the systemic inflammatory response in IL-6DC-OE
mice is dependent on the massive expansion of myeloid cells.
Initially, IL-6 was named “B cell hybridoma growth factor,”
to acknowledge its stimulatory function on B cells (18). Al-
though we did not detect robust expression of IL-6Ra on the
surface of B cells (Fig. 1D), IL-6 can pair with soluble IL-6Ra
and act on B cells expressing gp130. Importantly, a recent
study suggested that IL-6 can bind to CD5 on B cells and
activate STAT3 independently of IL-6Ra (7). Among B cells,
CD5 expression is rather restricted to B-1a cells, identifying
this subset as a primary target for the IL-6–CD5-signaling
module (19). Of note, mice with IL-6 overexpression on an
IL-6Ra–sufficient background exhibited a dramatic reduction
in B-1a cells in the spleen (Fig. 2B), whereas IL-6Ra defi-
ciency completely prevented the IL-6–triggered loss of B-1a
cells in IL-6DC-OE Il6ra2/2 mice (Fig. 2B).
FIGURE 1. IL-6Ra–dependent mortality of mice with IL-6 overexpression. (A) IL-6 levels in the blood serum of mice measured by ELISA. Dot plot graph
shows values for individual mice and mean per group. (B) CD11c-Cre–mediated IL-6 overexpression reported by eGFP coexpression in DCs in the spleen. Data
depict representative FACS plots with average frequencies per group. Three to four mice per group were used. For full gating strategy, refer to Supplemental Fig. 1B.
(C) Kaplan–Meier curves depict survival of the indicated mouse strains. (D) Median fluorescence intensity (MFI) of the IL-6Ra expression on splenocytes. Bar
diagram shows mean per group + SD. Isotype control was stained on corresponding cell populations isolated from Il6ra+/+ mice. Four mice per group were used. For
representative IL-6Ra FACS staining, refer to Supplemental Fig. 2A. (E) Western blot analysis of STAT3 phosphorylation in response to IL-6 stimulation in vitro
(10 ng/ml) of total splenocytes. Two-tailed unpaired t test was used for (A) and (D); Gehan–Breslow–Wilcoxon test was used for (C). All experiments were performed
two to three times with similar results. *p , 0.05, **p , 0.01, ***p , 0.001.
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Because CD4+ T cells expressed high levels of IL-6Ra
(Fig. 1D), we analyzed the T cell compartment in mice with
activated IL-6 pathway. We noted a significant shift toward
CD44+CD62L2 effector CD4+ T cells in the spleen of
IL-6DC-OE mice in comparison with the other groups tested
(Fig. 2C). However, the frequencies of effector CD4+ T cells in
response to exaggerated IL-6 expression became normal
again after IL-6Ra deletion. In accordance with a previous
report (20), we found abundant CD5 expression on CD4+
T cells, however, irrespective of their IL-6Ra status (Fig. 2D).
To test STAT3 activation in specific lymphocyte subsets in
mice with IL-6 overexpression, we performed immunoblotting
with lysates from CD19+ B cells and CD4+ T cells. Both cell
types isolated from IL-6DC-OE mice displayed STAT3 phos-
phorylation already in steady state without additional in vitro
IL-6 stimulation (Fig. 2E). Importantly, the steady-state
STAT3 phosphorylation (and also STAT3 phosphoryla-
tion in response to exogenous IL-6 stimulation in vitro) was
absolutely dependent on the presence of at least one copy of
Il6ra in CD19+ B cells and in CD4+ T cells (Fig. 2E).
In the current study, we observed a lethal immunopathology
in mice that overexpressed IL-6 as long as they were kept on an
IL-6Ra–sufficient background. Among several genetic models
with IL-6 overexpression (reviewed in Ref. 21), we activated
murine IL-6 overexpression driven by CAG promoter in a
CD11c-Cre–dependent manner. By genetic ablation of Il6ra,
the phenotype of profound immune dysregulation in mice
with transgenic IL-6 was completely rescued. This argues
against the biological significance of any IL-6 signaling sys-
tems that would be independent of IL-6Ra. In our model, we
cannot draw a definite conclusion as to which IL-6 signaling
modality (i.e., classic IL-6 signaling, IL-6 trans-signaling, or
IL-6 cluster signaling [trans-presentation]), is the most relevant
IL-6–signaling modality for the fatal immune dysregulation in
IL-6DC-OE mice. All three signaling modalities depend on
IL-6Ra, either on the side of the receiving cell (classic IL-6
signaling) or on the side of the donating cell in a soluble
manner (IL-6 trans-signaling) or in a cell-bound manner (IL-6
trans-presentation) (2, 6). In steady state, CD4+ T cells and
CD11b+ myeloid cells express relatively high levels of the
membrane-bound IL-6Ra. Thus, we speculate that, at least
initially, IL-6 overexpression is operational in lymphocytes
and myeloid cells through classic IL-6 signaling. The massive
expansion of granulocytes in IL-6DC-OE mice was a robust
FIGURE 2. IL-6 overexpression in mice leads to increased numbers of CD11b+ cells and affects the composition of the B and T cell compartment. (A) Fractions
and absolute numbers of neutrophils (Ly-6G+) and monocytes (Ly-6C+) in the spleen of the indicated mouse strains. (B) Fractions and absolute numbers of B-1a
cells (defined as VD2CD90.22CD19+IgM+CD232CD5+CD43+ cells) and B-1b cells (defined as VD2CD90.22CD19+IgM+CD232CD52CD43+ cells) in the
spleen of the indicated mouse strains. (C) Fractions and absolute numbers of naive (CD442CD62Lhigh) and effector (CD44+CD62L2) CD4+ T cells in the
spleen of the indicated mouse strains. (D) FACS analysis of CD5 expression on CD4+ T cells in the spleen of the indicated mouse strains. Data depict rep-
resentative FACS histograms with the definition of CD5-positive cells. Dot plot graphs depict mean fluorescence intensity (MFI) of CD5 expression and isotype
control for individual mice and mean per group. (E) Western blot analysis of STAT3 phosphorylation in response to IL-6 overexpression in vivo and to IL-6
stimulation in vitro (100 ng/ml) in CD19+ B cells and CD4+ T cells. Data (A–C) depict representative FACS plots with average frequencies per group. Dot plot
graph shows values for individual mice and mean per group. Three to four mice per group were used. Two-tailed unpaired t test was used for (A)–(D). All
experiments were performed two to three times with similar results. *p , 0.05, **p , 0.01, ***p , 0.001.
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observation. However, it remains to be determined whether the
expansion of Ly-6G+ cells in IL-6DC-OE mice is a direct effect of
IL-6. Recently, concerns have been raised as to whether circu-
lating granulocytes can directly respond to IL-6 (22).
Taken together, although we did not aim to dissect direct
and indirect effects of IL-6 overexpression in developing dev-
astating inflammation, our data compellingly support the ab-
solute requirement for IL-6Ra in mediating IL-6 effects in
mice. The fact that our study did not confirm the IL-6–CD5-
signaling module proposed for B cells (7) challenges the
biological significance of IL-6 signals transduced by an IL-6/
CD5/gp130 complex. Our conclusion is in accordance with
the recent finding that soluble CD5, despite binding of IL-6,
is unable to induce STAT3-mediated signal transduction in
gp130-expressing cells (8).
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Supplemental Figure 1. Generation and analysis of mice with IL-6 overexpression 
(Related to Figure 1). 
A – Breeding scheme to generate different groups of mice with IL6 overexpression. Tg - 
transgene; + - wild type (wt) allele; – - knock out allele; DC - dendritic cells; OE - 
overexpression. 
B – Gating strategy used for Figure 1B. After defining VD- live cells autofluorescence in FITC 
channel was excluded by using “NOT Boolean Gating” FlowJo algorithm. 
C – CD11c-Cre-mediated IL-6 overexpression followed by eGFP co-expression across 
different cell types in lymph nodes. Data depict representative FACS plots with average 
frequencies per group. Three to five mice per group were used. LN - pooled inguinal, brachial 
and axillary lymph nodes. All experiments were performed two to three times with similar 
results.  
Vi
aD
ye
-A
PC
-C
y7
FSC-H FSC-A SSC-H GFP-FITCSSC-H GFP-FITC
Vi
aD
ye
-A
PC
-C
y7
C
D
11
c-
PE
SS
C
-A
FS
C
-H
SS
C
-A
excluded
population
Gating strategy used for 
Figure 1B
- a representative example of 
the spleen sample from 
control mouse
B
C
Control IL-6DC-OE IL-6DC-OE Il6ra -/-Il6ra -/-
0.042.0
0.01
C
D
11
c
eGFP
0.05
0.00
1.224.2
2.33
1.9 0.601.5
2.75
0.043.9
0.02
C
D
11
b
eGFP
0.05
0.02
0.8420
2.75
3.9 0.614.3
2.76
0.0129
0.05
C
D
19
eGFP
0.01
0.06
0.6820
2.96
25 0.6121
2.77
0.0351
0.03
TC
R
β
eGFP
0.04
0.04
2.0435
1.60
52 2.1551
1.23
LN
(29%)(23% among
CD11c+)
(12%)(4% among
CD11b+)
(3%)(3% among
CD19+)
(4%)(6% among
TCRβ+)
A
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Supplemental Figure 2. Analysis of IL-6 singnaling modalities (Related to Figure 1). 
A – FACS analysis of IL-6Ra expression across different cell types in the spleen. Data depict 
representative FACS histograms indicating IL-6Ra+ cells within the respective parental 
population. Bar diagram shows mean per group + SD. Isotype control was stained on 
corresponding cell populations isolated from Il6ra+/+ mice. Four mice per group were used. 
Total cells defined as VD- live cells; CD4+ T cells defined as VD-CD19-TCRb+CD4+ cells; 
CD19+ B cells defined as VD-TCRb-CD19+ cells, CD11b+ cells defined as VD-CD19-TCRb-
CD11b+ cells. 
B – Western blot analysis of STAT3 phosphorylation in total splenocytes in response to IL-6 
stimulation in vitro (300 ng/ml). 
C – FACS analysis of STAT3 phosphorylation in response to in vitro stimulation with IL-6 
(50 ng/ml) and hyper-IL-6 (125 ng/ml). Mean fluorescence intensity (MFI) of p-STAT3 was 
normalized to the condition without stimulation (time point 0) per genotype. CD5- and CD5+ 
B cells were isolated from the peritoneal cavity, and CD5+CD4+ T cells were isolated from the 
spleen of Il6ra+/+ and Il6ra-/- mice, respectively. 
*p < 0.05, ***p < 0.001, N.S. – not significant; two-tailed unpaired t-test. All experiments were 
performed two to three times with similar results.
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Supplemental Figure 3. Analysis of different cell types in mice with IL-6 overexpression 
(Related to Figure 2). 
A – Fractions and absolute numbers of different leukocyte subsets in the spleen and lymph 
nodes of the indicated mouse strains. 
B – Cellularity in the spleen and lymph nodes of the indicated mouse strains. 
Dot plot graphs (A-B) show values for individual mice and mean per group. Three to five mice 
per group were used. LN - pooled inguinal, brachial and axillary lymph nodes; VD - Viability 
dye; cDC - conventional dendritic cells, defined as VD-CD19-TCRb-CD11b-CD11c+ cells; 
moDC - myeloid-derived dendritic cells, defined as VD-CD19-TCRb-CD11b+CD11c+ cells. 
*p < 0.05, **p < 0.01, ***p < 0.001, N.S. – not significant; two-tailed unpaired t-test. All 
experiments were performed two to three times with similar results.  
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Antigen Clone Supplier 
CD11b M1/70 Biolegend, eBioscience 
CD11c HL3  BD Biosciences 
CD11c N419 Biolegend 
CD19 6D5 Biolegend 
CD19 1D3 BD Biosciences 
CD23 B3B4 Biolegend 
CD4 RM4-5 Biolegend 
CD43 S7 BD Biosciences 
CD44 IM7 eBioscience 
CD45.1 A20 eBioscience 
CD45.2 104 Biolegend 
CD5 53-7.3 Biolegend 
CD62L MEL-14 eBioscience 
CD8 53-6.7 Biolegend 
CD90.2 30-H12 Biolegend 
CD90.2 53-2.1 Biolegend 
F4/80 CI:A3-1 abcam 
IgM II/41 eBioscience 
IL-6Ra D7715A7 BD Biosciences 
Ly-6C AL-21 BD Biosciences 
Ly-6G 1A8 Biolegend 
p-STAT3 (pY705) 4/P-STAT3 BD Biosciences 
TCRb H57-597 Biolegend, BD Biosciences 
   
Streptavidin   Biolegend 
   
IgG2a, k Isotype eBR2a eBioscience 
IgG2b, k Isotype R35-38 BD Biosciences 
   
Viability Dye   eBioscience, 65-0865 
Viability Dye   eBioscience, 65-0866 
 
Supplemental Table I. FACS antibodies and viability dyes used in the study. 
